Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

Theranexus presents new data on the stimulating effect of its drug candidate THN 102

05/07/2018
Download PDF file (306 Ko)

Half-year information on the liquidity contract (in French)

02/07/2018
Download PDF file (197 Ko)

Theranexus announces German Authorities approval for its phase 2 clinical trial in Parkinson's disease

26/06/2018
Download the PDF (375 Ko)

Theranexus announces the publication of a scientific article on the mechanism of action of drug candidate THN102 in the international journal of neuropsychopharmacology
22/05/2018
Download PDF file (262 Ko)

Theranexus publishes its cash position as at 31st March 2018
15/05/2018
Download PDF file (204 Ko)

Theranexus presentation at the International Connexins Symposium (Vancouver 14-15 May 2018)
07/05/2018
Download PDF file (273 Ko)

Oral presentation of Theranexus at the 9th European congress on narcolepsy 5 and 6 may in Montpellier
02/05/2018
Download PDF File (279 Ko)

Publication of 2017 reference document (in French)
27/04/2018
Download PDF file (153 Ko)

Theranexus announces its 2017 annual results and presents an update on the progress of its clinical trials
26/04/2018
Download PDF File (427 Ko)

THN102 obtains Investigational New Drug status from the Food & Drug Administration (FDA)
23/04/2018
Download PDF file (755 Ko)